<DOC>
	<DOCNO>NCT01502982</DOCNO>
	<brief_summary>The purpose test whether dose densified chemoimmunotherapy follow central nervous system ( CNS ) prophylaxis young high risk diffuse large B-cell lymphoma ( DLBCL ) patient feasible could improve time treatment failure reduce risk CNS relapse . Six course rituximab-cyclophosphamide-doxorubicin-etoposide-vincristine-prednison ( R-CHOEP ) give two week interval support G-CSF follow one course high dose methotrexate ( HD-MTX ) high dose cytarabine ( HD-Ara-C ) . The result compare historical Nordic study .</brief_summary>
	<brief_title>Dose Dense Chemotherapy Rituximab Young High Risk Diffuse Large B-Cell Lymphoma Patients ( CRY-04 )</brief_title>
	<detailed_description>Pathology : Patients may include base histological diagnosis local pathologist . The specimen review central pathologist country Treatment : All patient receive CHOEP-14 rituximab x 6 support G-CSF follow high dose cytarabine i.v . high dose methotrexate i.v.Intrathecal ( i.t . ) CNS prophylaxis combination chemotherapy give , i.t . methotrexate may give initial liquid sampling . Radiotherapy give discretion individual centre . Investigations , treatment : The disease status assess prior treatment start , 3 cycle CHOEP + rituximab completion treatment schedule . Positron Emission Tomography ( PET ) use F18 deoxyglucose may perform fulfillment treatment . Persistent , suspect lymphoma tissue whenever possible confirm biopsy , otherwise patient regard PR second line therapy consider ( see schematic outline ) . Clinical radiological ( CT ) assessment perform pretreatment subsequently sit initially involve , bone marrow biopsy initially involve - After 3rd course - After last course ( within one month ) chemotherapy ( biopsy indicate ) - After radiotherapy ( patient give radiotherapy part primary treatment ) Clinical follow-up : - 4x per year first second year follow-up - 2x per year third , fourth fifth year follow-up Radiological investigation follow : -CT 6 , 12 24 month sit initially involve . CT abdomen case 12 24 month . X-ray thorax ( CT thorax perform ) 6 , 12 24 month</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age â‰¥ 18 &lt; 65 year . 2 . Histology verify accord WHO classification CD20 positivity immunhistochemistry flow cytometry : Diffuse large Bcell lymphoma subgroup except posttransplantation , Burkittlike primary CNS lymphoma case leptomeningeal lymphoma involvement . Morphologically discordant lymphoma ( often follicular lymphoma diffuse large cell Bcell lymphoma different biopsy specimen , e.g . lymphatic gland bone marrow ) transform lymphoma include . Follicular lymphomas grade III The diagnosis make local pathologist participate centre accept registration 3 . Patients least stage II age adjust IPI score 2 3 : Stage III /IV elevate LDH and/or WHO performance status 2 3 Stage II elevate LDH WHO performance status 2 3 . 4 . Previously untreated . 5 . Performance status &lt; 4 ( Appendix 2 ) . 6 . Written inform consent 1 . Severe cardiac disease : cardiac function grade 34 ( Appendix 2 ) Left Ventricular Ejection Fraction ( LVEF ) &lt; 45 % ( base MUGA scintigraphy echo Doppler cardiography ) . 2 . Impaired liver , renal organ function cause lymphoma , interfere treatment schedule . 3 . Pregnancy . 4 . Men woman reproductive potential agreeing use acceptable method birth control treatment six month completion treatment . 5 . Patients severe medical problem expect short survival nonlymphoma reason . 6 . Known HIV positivity . 7 . Present previous cancer except basal cell carcinoma cervical carcinoma situ . 8 . Uncontrolled infectious disease . 9 . Psychiatric mental disorder make patient unable give inform consent and/or adhere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>high risk</keyword>
	<keyword>young</keyword>
</DOC>